At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new ...

Full-body MRIs are all the rage. We take a look at three major companies offering such testing.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

A new prostate imaging system for the detection of prostate cancer has been evaluated by Weiss and colleagues. Prostate mechanical imaging (PMI; Artann Laboratories, Trenton, NJ) is accomplished by ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...

Despite a decided shortage of placebo-controlled trials in humans to support that advice, the business of longevity is ...

Vir secured $335 million in upfront and near-term payments from its global collaboration with Astellas to advance VIR-5500.

The integration of genomic testing into cancer screening enables diagnostics to break away from conventional, one-size-fits-all protocols.